Omeros Corporation (NASDAQ:OMER) had its target price lowered by analysts at Wedbush from $56.00 to $47.00 in a research report issued to clients and investors on Wednesday. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Wedbush’s price target indicates a potential upside of 241.82% from the stock’s previous close.

A number of other brokerages also recently commented on OMER. Zacks Investment Research downgraded shares of Omeros Corporation from a “hold” rating to a “sell” rating in a report on Wednesday. Cantor Fitzgerald reiterated a “buy” rating and set a $21.00 price target on shares of Omeros Corporation in a report on Wednesday, August 10th. Maxim Group lowered their price target on shares of Omeros Corporation from $30.00 to $19.00 and set a “buy” rating for the company in a report on Wednesday, August 10th. FBR & Co reiterated a “buy” rating on shares of Omeros Corporation in a report on Thursday, November 10th. Finally, Needham & Company LLC lowered their price target on shares of Omeros Corporation from $28.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, November 10th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Omeros Corporation has an average rating of “Buy” and an average price target of $33.23.

Analyst Recommendations for Omeros Corporation (NASDAQ:OMER)

Shares of Omeros Corporation (NASDAQ:OMER) opened at 13.75 on Wednesday. The firm’s market capitalization is $590.08 million. Omeros Corporation has a 12-month low of $7.20 and a 12-month high of $16.80. The firm’s 50-day moving average is $9.49 and its 200-day moving average is $10.83.

Omeros Corporation (NASDAQ:OMER) last issued its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. The firm had revenue of $11.30 million for the quarter, compared to analysts’ expectations of $11.64 million. The business’s quarterly revenue was up 253.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.53) earnings per share. Equities research analysts forecast that Omeros Corporation will post ($1.68) EPS for the current fiscal year.

In other Omeros Corporation news, VP Marcia S. Kelbon sold 16,000 shares of the business’s stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $10.91, for a total transaction of $174,560.00. Following the completion of the sale, the vice president now directly owns 179,597 shares in the company, valued at $1,959,403.27. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 13.60% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the company. Ingalls & Snyder LLC increased its stake in Omeros Corporation by 15.2% in the third quarter. Ingalls & Snyder LLC now owns 5,085,949 shares of the biopharmaceutical company’s stock valued at $56,759,000 after buying an additional 671,370 shares in the last quarter. Bank of Montreal Can increased its stake in Omeros Corporation by 20.2% in the third quarter. Bank of Montreal Can now owns 2,015,248 shares of the biopharmaceutical company’s stock valued at $22,490,000 after buying an additional 338,263 shares in the last quarter. BlackRock Fund Advisors increased its stake in Omeros Corporation by 15.4% in the third quarter. BlackRock Fund Advisors now owns 1,701,287 shares of the biopharmaceutical company’s stock valued at $18,986,000 after buying an additional 226,724 shares in the last quarter. Vanguard Group Inc. increased its stake in Omeros Corporation by 2.3% in the second quarter. Vanguard Group Inc. now owns 1,430,125 shares of the biopharmaceutical company’s stock valued at $15,045,000 after buying an additional 32,401 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. increased its stake in Omeros Corporation by 11.4% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,016,293 shares of the biopharmaceutical company’s stock valued at $11,342,000 after buying an additional 104,092 shares in the last quarter. Institutional investors own 51.86% of the company’s stock.

Omeros Corporation Company Profile

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

5 Day Chart for NASDAQ:OMER

Receive News & Stock Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related stocks with our FREE daily email newsletter.